Pediatric Functional Constipation: Diagnosing It, Treating It, and Talking About It Without Losing the Family

 

NP CHRONICLES Clinical education for NP students & new grads

 

Pediatric Functional Constipation: Diagnosing It, Treating It, and Talking About It Without Losing the Family

A 2026 update on ESPGHAN/NASPGHAN guideline development, evidence-based management, and the communication traps that turn a routine diagnosis into a frustrated family.

🩺 CLINICAL BOTTOM LINE Functional constipation (FC) accounts for up to 35% of pediatric GI visits, yet families routinely leave the exam room feeling dismissed. Diagnosis is clinical (Rome IV) — imaging and labs are rarely needed. Treatment follows a two-phase pathway: disimpaction, then maintenance laxative therapy dosed and continued for months, not weeks. A major ESPGHAN/NASPGHAN guideline update (protocol published Feb 2025) is underway using GRADE methodology, and in June 2023 the FDA approved linaclotide as the first agent specifically labeled for pediatric FC (ages 6–17). Just as important as the regimen is the conversation: how you frame a normal workup and a functional diagnosis determines whether the family sticks with therapy for the months it actually takes to work.

 

Defining Functional Constipation

There is no single universally accepted definition of childhood constipation — and that ambiguity is part of why it's so often misdiagnosed or under-treated. Several frameworks are used in practice:

•    NASPGHAN: "a delay or difficulty in defecation, present for 2 weeks or more, and sufficient to cause significant distress to the patient."

•    Paris Consensus (PACCT): 8 weeks with at least 2 of — defecation frequency <3/week, fecal incontinence >1/week, large stools that clog the toilet, palpable abdominal/rectal fecal mass, stool-withholding behavior, or painful defecation.

•    Rome IV (the criteria most commonly used for guideline and research purposes) — see table below.

 

Rome IV Criteria for Functional Constipation

Infants and toddlers up to 4 years — must include ≥2 of the following for at least 1 month:

•    Two or fewer defecations per week

•    History of excessive stool retention

•    History of painful or hard bowel movements

•    Presence of large-diameter stools

•    History of a large fecal mass in the rectum

In toilet-trained children, either of these may also be used: at least 1 episode/week of incontinence after toileting skills are acquired, or a history of large-diameter stools that may obstruct the toilet.

 

Children and adolescents (developmental age ≥4 years) — must include ≥2 of the following, at least once per week for a minimum of 1 month, with insufficient criteria for IBS:

•    Two or fewer defecations in the toilet per week

•    At least one episode of fecal incontinence per week

•    History of retentive posturing or excessive volitional stool retention

•    History of painful or hard bowel movements

•    Presence of a large fecal mass in the rectum

•    History of large-diameter stools that can obstruct the toilet

After appropriate evaluation, symptoms cannot be fully explained by another medical condition.

 

📋 CASE FROM PRACTICE — Case 1 A 15-year-old presents for the third time with abdominal pain and consistently normal labs. She's missing school, falling behind in AP coursework, and at risk of being cut from the soccer team.   What the family hears when we say "everything looks normal": We don't know what's wrong with you.   Why that lands badly: heightened caregiver concern from the mismatch between real symptoms and normal testing, plus genuinely limited diagnostic value from repeating the same tests (Bouabida, Frontiers in Pediatrics 2026).   A better frame: "I know what is going on. More tests won't help." Normal results are diagnostic information, not a dead end — they support (not undermine) a functional diagnosis.

 

Pathophysiology: Why Withholding Becomes a Vicious Cycle

Most children with constipation have no underlying organic disease. The typical sequence: a painful bowel movement teaches the child to associate defecation with pain, prompting stool-withholding. In young children this is reflexive and pain-avoidant; in older children it can become more conscious, but it is still almost always about avoiding pain, not defiance. As withholding continues, the rectum gradually accommodates and the normal urge to defecate diminishes. Stool becomes larger and harder, reinforcing the pain association and worsening retention — with progressively abnormal defecation dynamics and anal sphincter spasm. Chronic rectal distention eventually causes loss of rectal sensitivity and loss of the urge to defecate, which is what produces fecal incontinence (encopresis) — involuntary overflow around a retained mass, not a hygiene or behavioral problem.

Onset commonly clusters around three transitions: dietary changes in infancy (breastmilk→formula, solids, formula→whole milk), toilet training in toddlerhood, and school entry in older children (reluctance to use the school bathroom).

 

📋 CASE FROM PRACTICE — Case 2 A 5-year-old has frequent stooling accidents at school, hides his soiled underwear, and hides while straining and grunting — then eventually passes a hard, painful stool.   What the family hears if we focus only on the straining: Your child strains when they're trying to poop — implying a simple mechanical or behavioral issue.   What's actually happening: stool-withholding leads to overflow incontinence. The universal instinct to avoid a painful bowel movement produces stereotypical posturing (stiffening, hiding, standing on tiptoe); hard retained stool then stretches the rectum, blunts sensation, and produces involuntary overflow (Di Lorenzo, Gastroenterology 2026).   A better frame: name what's actually happening physiologically, and reassure the family this is a recognized, treatable mechanism — not a defiance or hygiene problem — while being careful not to overstate the psychological framing (avoid language like implying trauma with every stool) that can alarm families without adding clinical value.

 

History and Physical Examination

Key History Points

•    Timing of first meconium passage — most Hirschsprung disease presents with delayed meconium (>36 hours) and constipation within the first 4–6 months of life.

•    Onset/duration of symptoms, pain with defecation, bleeding

•    Fecal incontinence or soiling — clarify this is not poor hygiene or diarrhea

•    Identifiable precipitating event (illness, diet change, toilet training, school entry)

 

Physical Exam

The rectal exam is the single most important component — perform it in any child with chronic constipation regardless of age, to exclude imperforate anus, mass effect, or Hirschsprung disease. In FC, the rectum is typically enlarged with stool present near the anal verge; in Hirschsprung disease, the rectum is characteristically empty and small, sometimes followed by a gush of stool after the exam (as the transient functional obstruction is relieved). Also examine for sacral dimples/pits (possible spinal cord abnormality), anal position, and anal wink reflex (stroke perianal skin — absence suggests a sensory/motor nerve or central pathway issue).

 

Workup: Less Is Usually More

Constipation is a clinical diagnosis. Labs are generally unnecessary unless an underlying condition (e.g., hypothyroidism, celiac disease, spinal/neuromuscular abnormality) is suspected. Despite evidence-based guidance against routine imaging, abdominal radiographs remain overused in the ED — one quality-improvement initiative cut radiograph rates from 62% to 24% simply through clinician education and shared best practices. Reserve abdominal x-ray for assessing fecal burden in children who are obese or who refuse a rectal exam, or when the history is ambiguous.

Reserve contrast enema, anorectal manometry, and rectal biopsy for suspected Hirschsprung disease — and if pursuing contrast enema, avoid air-contrast studies and any rectal manipulation (exam, enema, suppository) for 48 hours beforehand, since either can mask or falsely dilate the transition zone.

 

Treatment: Two Phases, Sustained Long Enough to Work

Phase 1 — Disimpaction

If a fecal impaction is present (palpable hard mass, dilated stool-filled rectum, or excess stool on radiograph), evacuate the colon first. Oral and rectal routes are equally effective in trials. Aggressive oral cathartics (polyethylene glycol [PEG], sodium phosphate, magnesium citrate, or a balanced PEG-electrolyte solution) or a series of enemas/suppositories can accomplish this. Young children who won't tolerate sufficient oral volume may need enemas or suppositories instead.

Phase 2 — Maintenance

Once evacuated, chronic laxative therapy is generally required to produce 1–2 soft stools daily — dosed high enough to eliminate pain with defecation entirely, even if that means larger-than-expected doses. PEG, mineral oil, magnesium hydroxide, and lactulose have all shown effectiveness and long-term safety. Stimulant laxatives (senna, bisacodyl) can be used intermittently but aren't recommended for routine long-term use in young children.

•    Establish regular toileting: 5–10 minutes on the toilet twice daily, ideally after meals, to leverage the gastrocolic reflex.

•    Continue laxative therapy for months, not weeks — discontinuing too early is a leading cause of relapse.

•    Warn families that relapse is common around routine disruptions (vacations, illness, stress) and that intermittent laxative use into adulthood is not unusual.

•    Address misconceptions proactively — long-term laxative use is not associated with dependency or colon cancer risk.

 

What Doesn't Clearly Help

Low-iron formula is unnecessary — iron-supplemented formula is not associated with increased constipation. Probiotic/synbiotic evidence is weak: a 52-RCT meta-analysis and a Cochrane review both found insufficient evidence for probiotics in pediatric functional constipation. Cow's-milk-protein avoidance is worth a trial in infants/young children with chronic constipation, since some data show high resolution rates with substitution (and recurrence on reintroduction) — but this is a targeted trial, not a default recommendation for all patients.

 

Novel and Emerging Therapies

In June 2023 the FDA approved linaclotide (Linzess) — a guanylate cyclase-C (GC-C) agonist — as the first agent specifically indicated for pediatric functional constipation, ages 6–17. In the pivotal phase 3 trial (n=328), linaclotide produced a greater than 2-fold increase in spontaneous bowel movements/week versus placebo (2.6 vs. 1.3, P<.0001). Other agents under the newer-therapies umbrella include lubiprostone, plecanatide, and bile acid modulators; non-pharmacologic adjuncts under study include pelvic floor biofeedback and interferential electrical/transcutaneous or sacral nerve stimulation.

 

What's New: The 2024–26 ESPGHAN/NASPGHAN Guideline Update

The last joint ESPGHAN/NASPGHAN pediatric FC guideline was published in 2014. A prospectively registered update protocol (Gordon et al., BMJ Paediatrics Open, Feb 2025) describes the standard operating procedure for the new guideline, which will use GRADE methodology throughout — including network meta-analysis to triangulate findings across pharmacologic, non-pharmacologic, and surgical interventions. A companion American Gastroenterological Association–NASPGHAN pediatric FC clinical care pathway was also published in 2026 (Rodriguez et al., Clin Gastroenterol Hepatol).

A notable methodological first: the Guideline Development Group ran a two-round Delphi process to prospectively define what counts as a trivial, small, moderate, or large treatment effect for each core outcome — before grading any evidence. That matters clinically because it sets an explicit bar for what a "statistically significant" trial result actually means for a patient. Selected absolute risk-difference thresholds for dichotomous efficacy outcomes:

 

Outcome (dichotomous)	Trivial→Small	Small→Moderate	Moderate→Large
Treatment success	7%	14%	24%
Improvement in defecation frequency	7%	15%	25%
Improvement in painful defecation	7%	13%	21%
Improvement in stool consistency	8%	15%	24%
Improvement in quality of life	9%	16%	24%
Improvement in fecal incontinence	8%	14%	22%
Improvement in abdominal pain	8%	14%	22%
Tolerability	7%	11%	17%

 

For continuous outcomes, the small-to-moderate thresholds include: an increase of ≥2.3 bowel movements/week, a decrease of ≥2.2 painful defecations/week, a ≥1.5-point shift on the Bristol Stool Form Scale, and a ≥23-point improvement on the PedsQL quality-of-life score. The guideline will also formally define faecal impaction and refractory constipation (persistent constipation despite two different-class laxatives, well-complied-with, over ≥3 months in a secondary/tertiary care setting) — both currently lack international consensus definitions.

 

The Conversation Is Part of the Treatment

A 2026 case report (Bouabida & Okang, Frontiers in Pediatrics) and a 2021 Rome Foundation communication-skills working team report (Drossman et al., Gastroenterology) both make the same point from different angles: how a functional GI diagnosis is delivered shapes whether families trust the plan enough to follow it for the months it takes to work. Below is a practical reframe for four common traps.

 

⚠️ COMMUNICATION REFRAMES Trap 1 — Normal results with no explanation. Family hears: "We don't know what's wrong with you." Say instead: "I know what is going on. More tests won't help." Normal labs support the diagnosis; repeat testing has limited added value.   Trap 2 — Framing it as psychological. Family hears: "It's all in your head." Say instead: "You are not making this up. This is very real and having a very real effect on your life." Anxiety/depression can coexist with — or result from — disorders of gut-brain interaction, but structural diagnoses are too often treated as more "legitimate" than functional ones. Don't reinforce that hierarchy.   Trap 3 — Implying nothing can be done. Family hears: "There's nothing we can do." Say instead: "I can help, but it will take your energy, effort, and above all, time." Pain from disorders of gut-brain interaction can be effectively managed with non-pharmacologic therapies (brain-gut psychotherapies) and neuromodulators — but only with buy-in for a sustained plan.   Trap 4 — Over-medicalizing a normal physiologic mechanism. Be precise about what's happening (stool-withholding → rectal distention → overflow incontinence) without dramatizing it in ways that alarm families without adding clinical value.

 

Board Prep: High-Yield Points

•    Rome IV is the criterion standard for defining pediatric FC in current guideline and research contexts — know the ≥2-of-6 (or ≥2-of-5 for <4 years) structure and 1-month duration.

•    Delayed meconium passage (>36 hours) + constipation onset in the first 4–6 months of life → think Hirschsprung disease, not FC.

•    On rectal exam: FC → dilated rectum, stool at the verge. Hirschsprung → empty, narrow rectum, possible post-exam gush of stool.

•    Do NOT use air-contrast enema when evaluating for Hirschsprung disease — it evacuates the colon and can mask the diagnostic transition zone. No rectal manipulation for 48 hours before a contrast enema.

•    Disimpaction (oral or rectal — equally effective) always precedes maintenance therapy.

•    PEG is first-line for maintenance in most guidelines; stimulant laxatives are for intermittent, not routine, use in young children.

•    Linaclotide (Linzess) — FDA-approved June 2023 for FC ages 6–17; mechanism is GC-C agonism → increased intracellular/extracellular cGMP → CFTR-mediated fluid secretion and accelerated transit.

•    Probiotics/synbiotics: current evidence does not support routine use for pediatric FC.

•    Encopresis = overflow incontinence around a retained fecal mass, not a hygiene issue — distinguish clearly from true diarrhea in patient/family education.

 

References

Gordon M, de Geus A, Banasiuk M, et al. ESPGHAN and NASPGHAN 2024 protocol for paediatric functional constipation treatment guidelines (standard operating procedure). BMJ Paediatr Open. 2025;9:e003161.

Borowitz SM. Pediatric Constipation. Medscape/eMedicine. Updated June 14, 2023.

Bouabida K, Okang M. Case Report: Breaking the cycle: preventing diagnostic escalation in pediatric chronic functional abdominal pain. Front Pediatr. 2026;14:1844256.

Di Lorenzo C, Saps M, Chumpitazi BP, et al. Lower and Biliary Disorders of Gut-Brain Interaction: Child and Adolescent. Gastroenterology. 2026;170(6):1367-1387.

Drossman DA, Chang L, Deutsch JK, et al. A Review of the Evidence and Recommendations on Communication Skills and the Patient-Provider Relationship: A Rome Foundation Working Team Report. Gastroenterology. 2021;161(5):1670-1688.e7.

Groen J, Gordon M, Chogle A, et al. ESPGHAN/NASPGHAN guidelines for treatment of irritable bowel syndrome and functional abdominal pain-not otherwise specified in children aged 4-18 years. J Pediatr Gastroenterol Nutr. 2025;81(2):442-471.

Keefer L, Ko CW, Ford AC. AGA Clinical Practice Update on Management of Chronic Gastrointestinal Pain in Disorders of Gut-Brain Interaction: Expert Review. Clin Gastroenterol Hepatol. 2021;19(12):2481-2488.e1.

Rodriguez L, Ambartsumyan L, Baumgartner K, et al. American Gastroenterological Association-North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Pediatric Functional Constipation Clinical Care Pathway. Clin Gastroenterol Hepatol. Published online April 2, 2026.

Tran P. "Trust Your Gut": A Practical Approach to Conversations About GI Problems in Children [CME slide deck]. Pri-Med Institute.

 

NP Chronicles  ·  Clinical education for NP students and new graduates since 2012